An anticancer approach that leads to improved tumor visibility edged closer to the clinic after Grey Wolf Therapeutics Ltd. scooped $49 million in a series B round. The Oxford, U.K.-based immuno-oncology company plans to use the proceeds to move its lead candidate, GRWD-5769, into a phase I/II trial.

Biopharmas raising money in public or private financings, including: Genelux, Harbour, HBN, Hemogenyx, Iaso, Inhibikase, Panbela, Tetra.

Coming off a tough year for raising money, Cadrenal Therapeutics Inc. is leading the charge into a new year by completing 2023’s first U.S. IPO. The company closed its IPO of 1.4 million shares at $5 each for $7 million. The stock (NASDAQ:CVKD) began trading Jan. 20 and closed 9.37% downward on Jan. 25 at $2.90 per share.

Biopharmas raising money in public or private financings, including: Atomic, Deciphera, Jasper, Myosana, Oxurion, Precigen, Pliant, Rewind, Verastem.

Biopharmas raising money in public or private financings, including: Apexigen, Cymabay, Pliant.

Biopharmas raising money in public or private financings, including: Adarx, Adipopharma, Alvotech.

Neophore Ltd. announced a £6 million (US$7.4 million) extension to its series B, bringing the total for the round to £21.5 million and enabling it to take forward a second DNA mismatch repair program.

Biopharmas raising money in public or private financings, including: Cadrenal, Deciphera, Endevica, Hemostemix, Mineralys, Windtree.

Biopharmas raising money in public or private financings, including: Bluebird, Deciphera, Deuteroncology, Neophore.